A single-gene test now offers a potential revival for ciprofloxacin as a gonorrhea treatment, providing a new method to combat a pathogen that has developed resistance to nearly all antibiotics. The test focuses on a specific mutation in the gyrA gene, which helps determine whether Neisseria gonorrhoeae remains treatable with ciprofloxacin—a drug previously abandoned due to widespread resistance. Given that ceftriaxone, the current standard treatment, now fails in over 25% of cases outside the U.S., this approach could reintroduce an oral alternative while preserving the last-resort injectable option.
Ciprofloxacin was discontinued in the early 2000s after resistance rates reached 5%, but roughly 60% of U.S. gonorrhea strains remain susceptible today. The test detects a mutation at codon 91 of the gyrA gene with 98% sensitivity and 98% specificity for predicting ciprofloxacin resistance, allowing clinicians to prescribe ciprofloxacin only when it will be effective. Clinical studies involving three trials demonstrate cure rates of 100% or greater than 98% across all infection sites, including the pharynx, where treatment success has historically been inconsistent even with ceftriaxone.
The test’s efficiency has improved since its introduction in 2017. Initial versions required 24 hours for results, but recent data indicates a processing time of about 2.5 days—a delay still preferable to patients, who would rather avoid an injection than wait. Since asymptomatic infections account for over half of all cases, clinicians have time to conduct the test before initiating treatment. An oral treatment option also eliminates the need for follow-up visits, reducing clinic workloads and enabling distribution through pharmacies or direct delivery to a patient’s sex partner.
This development extends beyond ciprofloxacin alone. Researchers are now applying the same approach to other antibiotics, such as cefixime, using CRISPR-based assays capable of identifying multiple resistance markers simultaneously. Lao-Tzu Allan-Blitz, MD, MPH, an assistant clinical professor at UCLA, has created point-of-care tests for gonorrhea detection and resistance profiling, including a lateral flow assay for urine samples.
His team is working to develop a full diagnostic panel that matches patients with the most targeted effective treatment—a critical advancement in regions where ciprofloxacin resistance already exceeds 99%, rendering it ineffective. Scaling resistance-guided therapy to low-resource settings, where most gonorrhea is still managed syndromically without diagnostic infrastructure, remains a substantial hurdle, though field-deployable assays have been piloted in Peru and are planned for sub-Saharan Africa.
In the U.S., regulatory and financial barriers remain the primary obstacles. The FDA has not yet approved any gyrA-testing devices, though a large trial supporting three applications is in its final stages, with clearance anticipated in early 2027. Reimbursement policies also pose a challenge, though a recent CPT code approval for a Mycoplasma genitalium resistance assay provides a potential model for Allan-Blitz’s team to follow. Without these regulatory and financial adjustments, widespread adoption of the test will remain stalled, despite its scientific promise.
Leave a Reply